These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 25380810)

  • 1. Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis.
    Neyt M; Hulstaert F; Gyselaers W
    BMJ Open; 2014 Nov; 4(11):e005922. PubMed ID: 25380810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis.
    Beulen L; Grutters JP; Faas BH; Feenstra I; van Vugt JM; Bekker MN
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():53-61. PubMed ID: 25238658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive prenatal screening for trisomy 21: what women want and are willing to pay.
    Verweij EJ; Oepkes D; de Vries M; van den Akker ME; van den Akker ES; de Boer MA
    Patient Educ Couns; 2013 Dec; 93(3):641-5. PubMed ID: 24011429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economic evaluation of noninvasive prenatal testing and serum screening for down syndrome.
    Xiao G; Zhao Y; Huang W; Hu L; Wang G; Luo H
    PLoS One; 2022; 17(4):e0266718. PubMed ID: 35421148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies.
    O'Leary P; Maxwell S; Murch A; Hendrie D
    Aust N Z J Obstet Gynaecol; 2013 Oct; 53(5):425-33. PubMed ID: 24090461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service.
    Morris S; Karlsen S; Chung N; Hill M; Chitty LS
    PLoS One; 2014; 9(4):e93559. PubMed ID: 24714162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population.
    Song K; Musci TJ; Caughey AB
    J Matern Fetal Neonatal Med; 2013 Aug; 26(12):1180-5. PubMed ID: 23356557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis.
    Fairbrother G; Burigo J; Sharon T; Song K
    J Matern Fetal Neonatal Med; 2016; 29(7):1160-4. PubMed ID: 26000626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cost-Effectiveness Analysis of Screening Strategies Involving Non-Invasive Prenatal Testing for Trisomy 21.
    Wang S; Liu K; Yang H; Ma J
    Front Public Health; 2022; 10():870543. PubMed ID: 35712262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down's syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units.
    Chitty LS; Wright D; Hill M; Verhoef TI; Daley R; Lewis C; Mason S; McKay F; Jenkins L; Howarth A; Cameron L; McEwan A; Fisher J; Kroese M; Morris S
    BMJ; 2016 Jul; 354():i3426. PubMed ID: 27378786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program.
    Ayres AC; Whitty JA; Ellwood DA
    Aust N Z J Obstet Gynaecol; 2014 Oct; 54(5):412-7. PubMed ID: 25196262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of prenatal screening and diagnostic strategies for Down syndrome: A microsimulation modeling analysis.
    Zhang W; Mohammadi T; Sou J; Anis AH
    PLoS One; 2019; 14(12):e0225281. PubMed ID: 31800591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rate of invasive testing for trisomy 21 is reduced after implementation of NIPT.
    Bjerregaard L; Stenbakken AB; Andersen CS; Kristensen L; Jensen CV; Skovbo P; Sørensen AN
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance and costs of contingent screening models for trisomy 21 incorporating non-invasive prenatal testing.
    Maxwell S; O'Leary P; Dickinson JE; Suthers GK
    Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):432-439. PubMed ID: 28369759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Women's preference for non-invasive prenatal DNA testing versus chromosomal microarray after screening for Down syndrome: a prospective study.
    Cheng Y; Leung WC; Leung TY; Choy KW; Chiu R; Lo TK; Kwok KY; Sahota DS
    BJOG; 2018 Mar; 125(4):451-459. PubMed ID: 29125674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant performances of non-invasive prenatal testing for foetal trisomy 21 screening in subgroups of pregnancies.
    Suo F; Wang Y; Wang N; Wang Y; Liao M; Wang J; Wang C; Zhang Y; Zhang M; Zhang C; Gu M; Gou L
    J Obstet Gynaecol; 2023 Dec; 43(2):2288226. PubMed ID: 38054928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of noninvasive prenatal testing as a diagnostic versus a screening tool--a cost-effectiveness analysis.
    Ohno M; Caughey A
    Prenat Diagn; 2013 Jul; 33(7):630-5. PubMed ID: 23674316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The consequences of implementing non-invasive prenatal testing with cell-free foetal DNA for the detection of Down syndrome in the Spanish National Health Service: a cost-effectiveness analysis.
    Bayón JC; Orruño E; Portillo MI; Asua J
    Cost Eff Resour Alloc; 2019; 17():6. PubMed ID: 30867656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advantages and Disadvantages of Different Implementation Strategies of Non-Invasive Prenatal Testing in Down Syndrome Screening Programmes.
    Mersy E; de Die-Smulders CE; Coumans AB; Smits LJ; de Wert GM; Frints SG; Veltman JA
    Public Health Genomics; 2015; 18(5):260-71. PubMed ID: 26202817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and effects of prenatal screening methods for Down syndrome and neural tube defects.
    Hoogendoorn M; Evers SM; Schielen PC; van Genugten ML; de Wit GA; Ament AJ
    Community Genet; 2008; 11(6):359-67. PubMed ID: 18690004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.